Diabetic Retinopathy Clinical Trials 2023

What are the top hospitals conducting diabetic retinopathy research?

In the realm of diabetic retinopathy, several hospitals are leading the charge in innovative clinical trials. Austin Retina Associates, located in Austin, stands at the forefront with six ongoing trials dedicated to this condition and a total of 11 completed studies thus far. Remarkably, their first recorded trial took place in 2012—an impressive testament to their commitment to advancing research on diabetic retinopathy. Moving westward to Bakersfield, California Retina Consultants is making significant strides as well. With four active trials and seven overall studies related to diabetic retinopathy under their belt since initiating their first trial in 2017, they have established themselves as key players in this field.

On the East Coast, Lynchburg's Piedmont Eye Center has emerged as another important institution for conducting clinical trials on diabetic retinopathy. Currently engaged in three active trials and boasting four previous studies dating back only a year ago when they conducted their inaugural investigation; it demonstrates increasing interest from both patients and researchers alike.

Further south, Palmetto Retina Center based out of West Columbia also focuses its efforts on combating diabetic retinopathy through three ongoing trials while contributing five comprehensive investigations since starting its medical journey just half a decade ago during 2016. Finally among these distinguished institutions is Bellaire's Retina Consultants of Texas where experts work diligently towards finding solutions for those affected by this debilitating eye disease.Headlining three current tests whilst having accumulated six compiled projects already within less than one year span; It showcases how committed these institutions are towards resolving any caught impacts due to Diabetic Retinoparthy

These hospitals serve as beacons of hope for individuals grappling with issues relating to vision loss caused by diabetes-related complications. By dedicating resources and expertise toward understanding better treatments or potential cure options through rigorous clinical research;they strive tirelessly every day.Constant evolution driven by relentless pursuit leads us closer than ever before - revealing promising future prospects that will enhance the quality of life for countless individuals affected by diabetic retinopathy throughout the globe.

Which are the best cities for diabetic retinopathy clinical trials?

When it comes to clinical trials for diabetic retinopathy, several cities have emerged as key players in research and development. Austin, Texas leads the pack with 15 ongoing trials focusing on treatments like Fenofibrate, Runcaciguat (BAY1101042), and OPL-0401 Dose 1. San Antonio, Texas follows closely behind with 11 active studies investigating interventions such as OTT166 and KSI-301. Lastly, Hagerstown, Maryland showcases its commitment to advancing care through 10 active trials studying Runcaciguat (BAY1101042), RGX-314 Dose 2, and other potential treatment options. These cities provide individuals with diabetic retinopathy access to cutting-edge clinical trials that may pave the way for improved management of this condition.

Which are the top treatments for diabetic retinopathy being explored in clinical trials?

Clinical trials investigating treatments for diabetic retinopathy have identified two top contenders. Financial Incentive, introduced in 2016, has shown promise and is currently being tested in two active trials dedicated to diabetic retinopathy. Another potential treatment is Sinemet CR, which made its debut in 2022 and is the focus of one ongoing trial specifically targeting this condition. These innovative therapies offer hope for improved management and outcomes for individuals affected by diabetic retinopathy.

What are the most recent clinical trials for diabetic retinopathy?

Exciting developments in the field of diabetic retinopathy research offer hope for improved treatment options. Recent clinical trials have explored various approaches to address this condition. One trial, known as 4D-150 Part 1 Dose Confirmation, focused on determining the appropriate dosage for treating diabetic retinopathy. Another study investigated the efficacy of foselutoclax as a potential treatment option. Additionally, Phase 2 Cohort B and Group 1 trials aimed to evaluate different interventions for managing diabetic retinopathy. Lastly, an innovative therapy called OTX-TKI underwent Phase 1 testing with promising results. These ongoing trials signify significant progress towards enhancing care and outcomes for individuals affected by diabetic retinopathy.

What diabetic retinopathy clinical trials were recently completed?

Recently, several clinical trials for diabetic retinopathy have concluded, bringing new insights and potential treatments to the forefront. In July 2021, Boehringer Ingelheim completed a trial examining the efficacy of BI 765128 in this condition. Ocuphire Pharma also made significant progress with their APX3330 trial, finishing in April 2021. Previous breakthroughs include Boehringer Ingelheim's completion of the BI 764524 trial in June 2020 and Hoffmann-La Roche's RG7774 trial concluding around the same time. Additionally, Adverum Biotechnologies successfully wrapped up their Aflibercept study in May 2020. These studies represent crucial milestones towards improving outcomes for individuals affected by diabetic retinopathy.